GMU’s Reverse-phase Protein Microarray Technology Included in I-SPY2 Breast Cancer Trial | GenomeWeb

This story originally ran on March 25.

By Tony Fong

A proteomic technology will be used to help discover and identify new biomarkers to evaluate five new investigational breast cancer drugs as part of one of the biggest screening trials for the disease.

Last week, the Biomarkers Consortium announced the launch of I-SPY2 for the screening and development of new drugs to treat high-risk, fast growing breast cancers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: mutations linked to nasopharyngeal carcinoma, salivary proteins common among oral squamous cell carcinoma patients, and more.

At Wired, a science journalist discusses her decision not to undergo BRCA testing.

The Japan Times says regulations are needed to oversee human genome-editing research.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.